CN116999346A - 一种低刺激高活性日间眼霜及其制备方法 - Google Patents
一种低刺激高活性日间眼霜及其制备方法 Download PDFInfo
- Publication number
- CN116999346A CN116999346A CN202310415179.6A CN202310415179A CN116999346A CN 116999346 A CN116999346 A CN 116999346A CN 202310415179 A CN202310415179 A CN 202310415179A CN 116999346 A CN116999346 A CN 116999346A
- Authority
- CN
- China
- Prior art keywords
- dimethicone
- stirring
- peg
- irritation
- eye cream
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006071 cream Substances 0.000 title claims abstract description 23
- 230000000694 effects Effects 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 23
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 claims abstract description 17
- 239000000284 extract Substances 0.000 claims abstract description 16
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003094 microcapsule Substances 0.000 claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 8
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims abstract description 7
- 229960003232 troxerutin Drugs 0.000 claims abstract description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 6
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960001948 caffeine Drugs 0.000 claims abstract description 6
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims description 32
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 28
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 27
- -1 polydimethylsiloxanes Polymers 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 230000007794 irritation Effects 0.000 claims description 10
- 230000001804 emulsifying effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical group CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 239000002738 chelating agent Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229920006037 cross link polymer Polymers 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 6
- 241000219195 Arabidopsis thaliana Species 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 229930003799 tocopherol Natural products 0.000 claims description 5
- 239000011732 tocopherol Substances 0.000 claims description 5
- 235000010384 tocopherol Nutrition 0.000 claims description 5
- 229960001295 tocopherol Drugs 0.000 claims description 5
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 241000157282 Aesculus Species 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 235000010181 horse chestnut Nutrition 0.000 claims description 3
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 claims description 2
- RWLALWYNXFYRGW-UHFFFAOYSA-N 2-Ethyl-1,3-hexanediol Chemical compound CCCC(O)C(CC)CO RWLALWYNXFYRGW-UHFFFAOYSA-N 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- SHOKSIZSCQFIRY-UHFFFAOYSA-N [3-(2-tert-butyl-2-hydroxy-4,4-dimethyl-3-phenylpentanoyl)oxy-2,2-bis[(2-tert-butyl-2-hydroxy-4,4-dimethyl-3-phenylpentanoyl)oxymethyl]propyl] 2-tert-butyl-2-hydroxy-4,4-dimethyl-3-phenylpentanoate Chemical compound C=1C=CC=CC=1C(C(C)(C)C)C(O)(C(C)(C)C)C(=O)OCC(COC(=O)C(O)(C(C=1C=CC=CC=1)C(C)(C)C)C(C)(C)C)(COC(=O)C(O)(C(C=1C=CC=CC=1)C(C)(C)C)C(C)(C)C)COC(=O)C(O)(C(C)(C)C)C(C(C)(C)C)C1=CC=CC=C1 SHOKSIZSCQFIRY-UHFFFAOYSA-N 0.000 claims description 2
- FENRSEGZMITUEF-ATTCVCFYSA-E [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] FENRSEGZMITUEF-ATTCVCFYSA-E 0.000 claims description 2
- 210000000026 apposition eye Anatomy 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 claims description 2
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 229940113120 dipropylene glycol Drugs 0.000 claims description 2
- CNRDTAOOANTPCG-UHFFFAOYSA-N dodecyl carbamate Chemical compound CCCCCCCCCCCCOC(N)=O CNRDTAOOANTPCG-UHFFFAOYSA-N 0.000 claims description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229960005082 etohexadiol Drugs 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 229940051250 hexylene glycol Drugs 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229920001427 mPEG Polymers 0.000 claims description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 229940116351 sebacate Drugs 0.000 claims description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 229940083982 sodium phytate Drugs 0.000 claims description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 2
- 229940042585 tocopherol acetate Drugs 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 16
- 229940008099 dimethicone Drugs 0.000 claims 11
- 235000011187 glycerol Nutrition 0.000 claims 2
- 229940099549 polyglycerin-3 Drugs 0.000 claims 2
- 229940110977 polyglycerin-4 Drugs 0.000 claims 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 1
- PAFJZWHXMSQJKV-UQZRNVAESA-N (3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol;octadecanoic acid Chemical compound OC[C@@H](O)C1OC[C@H](O)[C@H]1O.OC[C@@H](O)C1OC[C@H](O)[C@H]1O.OC[C@@H](O)C1OC[C@H](O)[C@H]1O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O PAFJZWHXMSQJKV-UQZRNVAESA-N 0.000 claims 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims 1
- DJXPNUIRGNRCPQ-UHFFFAOYSA-N 2-[2,3-bis[2-(16-methylheptadecanoyloxy)ethoxy]propoxy]ethyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCCOCC(COCCOC(=O)CCCCCCCCCCCCCCC(C)C)OCCOC(=O)CCCCCCCCCCCCCCC(C)C DJXPNUIRGNRCPQ-UHFFFAOYSA-N 0.000 claims 1
- AKWFJQNBHYVIPY-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO AKWFJQNBHYVIPY-UHFFFAOYSA-N 0.000 claims 1
- 229940082500 cetostearyl alcohol Drugs 0.000 claims 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 abstract description 3
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 abstract description 3
- 241000219194 Arabidopsis Species 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 65
- 239000000523 sample Substances 0.000 description 43
- 210000003491 skin Anatomy 0.000 description 35
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 13
- 108010035532 Collagen Proteins 0.000 description 13
- 229920001436 collagen Polymers 0.000 description 13
- 239000003642 reactive oxygen metabolite Substances 0.000 description 12
- 241000252212 Danio rerio Species 0.000 description 11
- 102000019197 Superoxide Dismutase Human genes 0.000 description 11
- 108010012715 Superoxide dismutase Proteins 0.000 description 11
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 10
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000037303 wrinkles Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical group CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 150000003700 vitamin C derivatives Chemical class 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000036564 melanin content Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 229940120155 3-o-ethyl ascorbate Drugs 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 101100438273 Arabidopsis thaliana CAN1 gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 101710183568 Serine/threonine-protein kinase PknK Proteins 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008789 oxidative DNA damage Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229940105297 polyglyceryl-2 diisostearate Drugs 0.000 description 1
- 229940100518 polyglyceryl-4 isostearate Drugs 0.000 description 1
- 230000000270 postfertilization Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
Abstract
本发明属于轻化工中的化妆品技术领域,尤其涉及一种低刺激高活性日间眼霜及其制备方法。其组成及重量份数为,VC‑IP3~10份,VC乙基醚2~5份,缓释微囊体0~1份,曲克芦丁0.1~1份,浮游生物提取物溶液0.1~2份,拟南芥提取物溶液0.1~2份,环糊精包裹的咖啡因1~8份,七叶树皂苷0.1~2份,双效肉毒肽为1~10份,其它基础成分加至100份。
Description
技术领域:
本发明属于轻化工中的化妆品技术领域,尤其涉及一种低刺激高活性日间眼霜及其制备方法。
背景技术:
化妆品中的日霜除有修护、保湿、抗皱、紧肤的作用外,最大特色还是在于可以防御环境(如紫外线、空气污染物)对肌肤的伤害。从市售日霜的成分看,大多不会脱离日霜的防护、隔离功能,因为在这些产品中多具有SPF防晒系数,或紫外线过滤剂,适合在白天出门前使用。随着市场上早C晚A的潮流发展,维C及其衍生物相关的面霜受到消费者的青睐。这主要是因为维生素C具有很强的抗氧化性,在早上使用含维生素C的护肤品能帮助清除体内有害自由基,这样能减少紫外线对皮肤的损伤,能有效对抗光老化,长期如此能起到美白的效果。然而维C对皮肤有一定刺激性,浓度越高,刺激性越大,对于敏感肌来说需要谨慎使用。因此出现了系列的维C衍生物,例如VC-乙基醚,VC-IP(VC四异棕榈酸酯)、VC硬脂酸酯、VC磷酸盐等;其中VC乙基醚和VC-IP属油溶性的VC衍生物,适合被人体皮肤吸收(表皮层细胞膜是亲油的)。VC-IP抗坏血酸四异棕榈酸酯是一种油溶性维生素C衍生物,稳定性高,不易被氧化。VC-IP抗坏血酸四异棕榈酸酯具有优异的透皮吸收并转化为维C的能力,VC-IP抗坏血酸四异棕榈酸酯一方面能中断黑色素的合成并且能淡化已生成的黑色素;另一方面VC-IP抗坏血酸四异棕榈酸酯能有效穿透渗入到肌肤,直接刺激肌底的胶原蛋白组织,促进胶原蛋白的生成,预防皮肤老化。而维生素C乙基醚是一种非常有用的维生素C衍生物,它不仅在化学物质上非常稳定,是不变色的维生物C衍生物,而且是亲油亲水两性物质,这大大的扩展了他的适用范围,尤其是在日用化学中应用。3-O-乙基抗坏血酸醚很容易通过角质层进去真皮层,它进入机体后非常容易体内的生物酶分解从而发挥维生素C的生物学功效。在稳定性和功效性上,油溶性VC衍生物均比水溶性VC有一定优势。
在高含量VC-IP和VC乙基醚基础上,为了达到温和(无刺激)的效果,我们还需要应用一定的缓释技术:该缓释包裹载体由卵磷脂、甘油、1,2-戊二醇、生育酚(VE)、水组成。它的优势在于(1)提高生物利用度的天然载体;(2)与水简单混合即能形成稳定的脂质体;(3)无需高剪切混合即能形成小粒径(200nm);(4)增强亲水性活性物的渗透性,易于使用的体系;(5)用不饱和非转基因大豆磷脂制成的未封装脂质体浓缩物,技术人员可自行包裹。
除了VC及其衍生物系列原料可以抗紫外线损伤,另外还有曲克芦丁可以阻挡蓝光,抑制UVB诱导的HaCaT细胞(人永生化角质形成细胞)凋亡,抑制MAPK信号途径转导及转录因子AP-1(c-Fos和c-Jun),从而起到抗光损伤的作用。并且,通过调节相关的miRNAs的表达来保护nHDFs(成纤维细胞)免受紫外线诱导的氧化应激和DNA损伤。浮游生物提取物可以大幅度减少UV光引起的MMP-1表达。拟南芥可以高效清除UV光产生的氧化损伤标志物8-oxo-Gua,保护线粒体机能,修复ROS带来的DNA损伤。
日霜中对黑眼圈的改善主要来自三个方面:1)抑制眼部周围胶原蛋白的分解,2)减少黑色素沉积;3)促进血液循环,加速新陈代谢,增加静脉张力,改善微循环(血管型)。抗眼袋主要依靠即使效果和长期效果实现,例如双效肉毒肽可以突出前后机理结合的双效类肉毒素,而长期需要胶原蛋白的生长和血液循环实现。
发明内容:
本发明正是针对上述问题,提供了一种低刺激高活性日间眼霜及其制备方法。
为了实现上述目的,本发明采用如下技术方案,其组成及重量份数为,VC-IP(抗坏血酸四异棕榈酸酯)3~10份,VC乙基醚(3-邻-乙基抗坏血酸)2~5份,缓释微囊体0~1份,曲克芦丁0.1~1份,浮游生物提取物溶液0.1~2份(水/浮游生物提取物/卵磷脂/苯乙醇/对羟基苯乙酮=97:1:1:0.5:0.5),拟南芥提取物溶液(水/拟南芥提取物/卵磷脂/苯乙醇/对羟基苯乙酮=97:1:1:0.5:0.5)0.1~2份,环糊精包裹的咖啡因(各占50%)1~8份,七叶树皂苷0.1~2份;双效肉毒肽(水/甘油/辛甘醇/乙酰基六肽-1=94.4%:5%:0.5%:0.1%)为1~10份,其它基础成分(加至100份)。
所述的缓释微囊体由水、卵磷脂、甘油、1,2戊二醇、生育酚(维生素E)、氢氧化钠通过高压微射流技术得到;与水简单混合即能形成稳定的脂质体,无需高剪切混合即能形成小粒径(200nm),主要是增强亲水性活性物的渗透性,易于使用的体系。
所述的基础成分包括溶剂、螯合剂、保湿剂、防腐剂、pH调节剂、抗氧化剂、乳化剂、增稠剂、填充剂。
所述的溶剂为去离子水,螯合剂为EDTA-2钠和/或植酸钠。
所述的保湿剂为多元醇(甘油、戊二醇、丁二醇、丙二醇、己二醇、辛甘醇、双丙甘醇、甲基丙二醇等)、聚二甲基硅氧烷(包括不同粘度)、C10-18脂酸甘油三酯类、辛酸/癸酸甘油三酯中的一种或者多种;
防腐剂为对羟基苯乙酮和/或苯氧乙醇;
pH调节剂为精氨酸、氢氧化钠、柠檬酸钠、柠檬酸中的一种或者多种;
抗氧化剂为生育酚乙酸酯、生育酚、季戊四醇四(双-叔丁基羟基氢化肉桂酸)酯中的一种或者多种。
所述的乳化剂为双-PEG/PPG-20/5PEG/PPG-20/5聚二甲基硅氧烷、甲氧基PEG/PPG-25/4聚二甲基硅氧烷、鲸蜡硬脂醇、菊粉月桂基氨基甲酸酯、聚甘油-2二异硬脂酸酯、聚甘油-3聚二甲基硅羟乙基聚二甲基硅氧烷、PEG/PPG-14/7二甲基醚、月桂基PEG/PPG-18/18聚甲基硅氧烷、PEG/PPG-18/18聚二甲基硅氧烷、月桂基PEG-10三(三甲硅氧烷)甲硅烷氧乙基聚二甲基硅氧烷、鲸蜡基PEG/PPG-10/1聚二甲基硅氧烷、聚甘油-4异硬脂酸酯、聚甘油-4二异硬脂酸酯/聚羟基硬脂酸酯/癸二酸酯、山梨坦倍半油酸酯、山梨坦倍半异硬脂酸酯、PEG-20甘油三异硬脂酸酯、PEG-40氢化蓖麻油、聚甘油-3聚蓖麻醇酸酯、聚甘油-6聚蓖麻醇酸酯、月桂基PEG-9聚二甲基硅氧乙基聚二甲基硅氧烷、PEG-30二聚羟基硬脂酸酯、双-PEG/PPG-14/14聚二甲基硅氧烷中的一种或者多种;
增稠剂为丙烯酰二甲基牛磺酸铵/VP、PVP共聚物中的一种或者多种;
填充剂(硅弹体)为聚二甲基硅氧烷/乙烯基三甲基硅烷氧基硅酸酯交联聚合物、聚二甲基硅氧烷交联聚合物、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物中的一种或者多种。
具体的制备方法为,
1、将溶剂、防腐剂、螯合剂、保湿剂加入到水相锅中,保持温度35~45℃,搅拌速度30~50r/min,恒温搅拌10~30min,均质5~15min,均质速度为2000~3500r/min,直到水相中物料完全溶解均匀,然后将增稠剂加入水相锅中进行溶解,得到具有一定稠度的液体,保持35~40℃,然后加入环糊精包裹的咖啡因、曲克芦丁、双效肉毒肽、浮游生物提取物溶液、拟南芥提取物溶液、七叶树皂苷,继续搅拌至溶解;
2、将抗氧化剂、乳化剂、填充剂加入到乳化锅中,保持温度65~85℃,搅拌速度30~50r/min,恒温搅拌10~30min,均质5~15min,均质速度为2000~3500r/min,直到物料完全溶解均匀,降温至35~40℃;
3、将步骤1制得的混合物料边搅拌边缓慢加入到步骤2的乳化锅中,继续搅拌直至溶解;
4、预处理过程,将VC-IP和VC乙基醚加入到缓释微囊体中高速搅拌3500~10000rpm,直至溶液均匀分散;
5、将步骤4预处理后的物料加入到步骤3的乳化锅中,保持原有温度继续搅拌,搅拌速度30~50r/min,然后加入pH调节剂调节体系的PH值为4.0~7.5,,继续搅拌;
6、最后将混合物料降温至25~38℃,检验、过滤、出料。
本发明的有益效果:
1、本发明解决了日间眼霜中VC类产品功效快但刺激性大的问题,采取了缓释包裹载体技术,引入了卵磷脂的复合结构;因此得到了功效快、功效改善明显并且温和性较高的产品。
2、本发明从三个维度上提高了日间眼霜的功效性:抗紫外损伤,改善黑眼圈和眼袋,并且考虑到了及时和长期效果。及时效果主要是依靠维生素C及其衍生物、肉毒肽,长效主要是植物提取物等。并且从机理上,全方位的解决白日中皮肤所遇到的问题,包括减少UV引起的DNA损伤、MMP-1表达,线粒体机能损伤、黑色素沉积、胶原蛋白分解、血液循环受阻、新陈代谢变慢、皮肤血管微循环受阻等。因为机体是一个复杂的综合体,需要多方位各个方面解决皮肤问题才能达到优异的效果。
附图说明:
图1为斑马鱼温和(无刺激)测试典型图,a为对照组,b为实施例1样品组。
图2为Sunburn Cell部分测试结果图:组织形态图片部分汇总。
图3为Nrf2部分图片汇总图。
图4为ROS部分图片汇总图。
图5为部分受试者使用实施例1后眼周围皮肤胶原密度图。
图6为部分受试者使用实施例1后,VISIA拍照部分受试者眼周皱纹状况图;受试者分别为44岁,44岁,47岁。
图7为实施例5中眼周黑色素(黑眼圈)和眼部皱纹测试的测试部位演示图。
具体实施方式:
实施例
实施例1-4的配方详见下方的表1。
表1
实施例1-4的制备过程为,
1、将A相中各物料加入到水相锅中,保持温度35-45℃,搅拌30-50r/min,恒温搅拌10-30min,均质5-15min,均质速度为2000-3500r/min,直到水相中物料完全溶解均匀,然后将B相加入A相中进行溶解,得到具有一定稠度的液体。保持35-40℃然后加入C相功效物质,继续搅拌溶解。
2、将D相中的各物料加入到乳化锅中,保持温度65-85℃,搅拌30-50r/min,恒温搅拌10-30min,均质5-15min,均质速度为2000-3500r/min,直到D相中物料完全溶解均匀,降温至35-40℃将水相锅中混合物料边搅拌边缓慢加入到乳化锅中,继续搅拌直至溶解。
3、预处理E相,将VC-IP和VC乙基醚加入到缓释微囊体中高速搅拌3500-10000rpm,直至溶液均匀分散。(实施例4除外,没有微囊体,不需要预处理)
4、将预处理的E相加入到乳化锅中保持原有温度搅拌30-50r/min,然后加入F相,继续搅拌30-50r/min。
5、最后降温至25-38℃左右,检验、过滤、出料。
对比例1
市场上含VC或者其衍生物的日霜(市场上宣称早C晚A中的早C日霜)。
对比例2
与实施例1的区别为,不含环糊精包裹的咖啡因、曲克芦丁、双效肉毒肽、浮游生物提取物溶液、拟南芥提取物溶液、七叶树皂苷、VC-IP、VC乙基醚和缓释微囊体。
实施例5性能测试
1、温和性测试
测试方法:斑马鱼温和(无刺激)试验方法
方法来源:《斑马鱼温和(无刺激)评价实验标准操作规程》
样本说明:试验体系:转基因中性粒细胞绿色荧光斑马鱼(MPX)。斑马鱼鱼龄:受精后2天(2dpf)。每组实验样本量:15尾(N=10)。成鱼饲养及繁殖方法:按照本公司实验室标准饲养和繁殖方法,符合国际AAALAC认证(认证编号:001458)的要求。
测试原理方法:样品中刺激性物质作用于机体后可能引发机体产生刺激、过敏等一系列的生理、生化反应,其中最主要的是刺激反应,可导致水肿、红斑、瘙痒、疼痛等症状。样品对皮肤的刺激表型主要表现为皮肤炎症,炎症早期主要表现为毛细血管扩张、通透性亢进和水肿。刺激物进入斑马鱼体内,诱导炎症反应,中性粒细胞发生免疫应答,向皮肤表皮迁移并聚集。利用转基因中性粒细胞绿色荧光品系斑马鱼(MPX)处理前后皮肤中性粒细胞数量变化来检测样品是否温和(无刺激)。
实验步骤:
(1)随机选取斑马鱼于6孔板中,每孔15尾。
(2)水溶给予样品,同时设置正常对照组,每孔容量为3mL。
(3)28℃条件下避光孵育18h。
(4)每个实验组随机选取10尾斑马鱼置于荧光显微镜下拍照,用高级图像处理软件分析并采集数据,分析斑马鱼皮肤中性粒细胞数量(N),根据公式计算样品刺激性,判断其是否温和(无刺激)。
刺激性%=(N样品组-N正常对照组)/N正常对照组×100%
判定依据:统计学分析p<0.05,判定为有显著性差异。
表2检测结果
结论:观察发现,实施例1、2、3和对比例2样品中性粒细胞数量与正常对照组相似,揭示了该样品温和(无刺激);而实施例4和对比例1刺激性比较显著。实施例4没有用微囊包裹技术,在VC-IP和VC乙基醚含量较高的情况下出现了一定的刺激反应。
2、抗UV损伤测试
测试目的:采用UVB刺激3D表皮皮肤模型构建体外皮肤损伤模型,通过检测样品作用后组织形态Sunburn Cell,MDA,SOD,ROS(活性氧)、核转录因子Nrf2含量的变化,评价待测样品UV损伤后的抗氧化作用。
测试材料:3D皮肤模型,由广东博溪生物科技有限公司提供。
主要设备:UVB照射仪(博溪生物)、酶标仪(BioTek,Epoch),高效液相色谱仪(安捷伦1260),荧光显微镜(Leica,DM2500),正置显微镜(Olympus,BX53)
测试方案设计:
表3测试方案
模型给药:
(1)根据表1的测试方案,将模型转移到6孔板中,(提前添加0.9mL相应分组的EpiGrowth培养液),在6孔板上标注测试组编号;
(2)样品组工作液加于模型表面,将模型置于CO2培养箱(37℃,5%CO2)中继续孵育24h;
(3)孵育结束后,用无菌PBS清洗模型表面残留的受试物,用无菌棉签拭去模型内、外残留液体。
组织形态测试:取用于组织形态测试的模型,环切取下,用4%多聚甲醛固定处理,固定24h,进行H&E染色检测,显微镜拍照观察,采集图片、测量和计算活细胞层厚度进行分析。
MDA测试:将模型环切至1.5mL EP管中,每管加入500uL 0.2mg/mL蛋白激酶K,置于50℃水浴1h,待角质层脱落后,每管加入250uL的甲醇,超声30min,然后14000rpm离心10min。60℃蒸干甲醇,保存4℃中,用于上机准备。
免疫荧光测试:取用于检测的模型环切取下,用4%的多聚甲醛进行固定处理,固定24h后,进行Nrf2免疫荧光检测,显微镜拍照观察并分析数据。
活性氧(ROS)含量测试:
(1)探针工作液配制:用模型培养液将10mM的探针溶液稀释微20uM的探针工作液。
(2)探针孵育:将模型转移到6孔板,每孔添加0.9mL 20uM的探针工作液;模型随机分为空白对照组(BC)、阴性对照组(NC)、阳性对照组(PC)和样品组,每组3个重复。于CO2培养箱(37℃、5%CO2)孵育1h,每隔20min晃动孔板一次,保证模型孵育均匀。
(3)辐照:探针孵育结束后,用PBS冲洗模型底部,将清洗后的模型转移至含PBS的6孔板中,置于UVB辐照下照射(辐照剂量为600mJ/cm2)。
(4)模型给药:模型辐照结束后,吸弃孔板中的培养液;BC组、NC组及样品组每孔添加0.9mL正常模型培养液,PC组每孔添加0.9mL含有7ug/mL VE的模型培养液。且样品组以相应样品进行处理,给药方式采用表面给药,给药体积以25uL/模型进行,给药时以轻柔打圈的方式尽量涂抹均匀,以保证样品充分吸收。
(5)模型培养:给药完成后,将6孔板置于CO2培养箱(37℃、5%CO2)中,继续孵育24h.
(6)收样,24h孵育结束后,立即切取模型,置于1.5mL EP管中,并在管中加1mL 4%多聚甲醛固定液,用锡箔纸包覆,送样做冰冻切片。
(7)清洗切片和封片:将切好的冰冻切片用PBS清洗8min,清洗结束后,用吸水纸将组织周围的液体擦拭干净,用200uL枪头滴一小滴(20uL左右)荧光抗猝灭封片剂,轻轻盖上盖玻片封片。
(8)观察和数据分析。
超氧化物歧化酶(SOD)含量测试:UVB辐射后,将模型放入培养箱(37℃,5%CO2)继续培养24h,PBS清洗模型3次,根据SOD试剂盒操作说明书进行检测。
统计结果分析:应用GraphPad Prism作图,结果表示Mean±SD,P<0.05认为显著差异,P<0.01认为具有极其显著差异。
表4活细胞层厚度数据
与BC相比,NC活细胞层厚度显著降低,说明本次测试刺激条件有效,与NC相比,PC活细胞层厚度显著上升,说明本次测试阳性对照有效。与NC相比,实施例1样品的细胞层厚度显著上升,其次是实施例3和实施例4,也是显著上升;而对比例1、实施例2和对比例2的细胞层厚度无显著差异。对比例2与实施例1对比不含功效成分,无抗紫外效果,而实施例2由于其功效活性物含量较低,效果不明显。
MDA测试结果
表5 MDA数据汇总表
与BC相比,NC的MDA含量显著上升,说明本次测试刺激条件有效,与NC相比,PC的MDA含量显著下降,说明本次测试阳性对照有效,与NC相比,实施例1、对比例1、实施例3和实施例4样品的MDA含量显著下降,而实施例2和对比例2样品的MDA含量下降不明显。
Nrf2测试结果
表6 Nrf2结果汇总表
与BC相比,NC的Nrf2含量显著下降,说明本次测试刺激条件有效,与NC相比,PC的Nrf2含量显著上升,说明本次测试阳性对照有效,与NC相比,实施例1样品、对比例1的Nrf2含量显著上升,而实施例2和对比例2样品的Nrf2含量变化不明显。
活性氧(ROS)测试结果
表7活性氧(SOD)结果汇总表
与BC相比,NC的ROS含量显著上升,说明本次测试刺激条件有效,与NC相比,PC的ROS含量显著下降,说明本次测试阳性对照有效,与NC相比,实施例1样品的ROS含量显著下降。实施例2和对比例2样品的ROS含量无显著变化。
超氧化物歧化酶(SOD)测试结果
表8 SOD结果汇总表
与BC相比,NC的SOD酶活力显著下降,说明本次测试刺激条件有效,与NC相比,PC的SOD酶活力显著上升,说明本次测试阳性对照有效,与NC相比,实施例1样品、对比例1竞品的SOD酶活力显著上升。
3、眼周黑色素(黑眼圈)和眼部皱纹测试
测试依据:采用人体功效测试方法,参照T/ZHCA 006-2019《化妆品抗皱功效测试方法》以及欧洲化妆品及其他外用产品功效评价协会(EEMCO)--皮肤纹理评价指南:Guidance for the Assessment ofSkin Topography;皮肤颜色:guidance for theassessment of skin color,并配合文献资料《Global periorbital skin rejuvenationby atopical eye cream containing low molecularweight heparan sulfate(LMW-HS)and a blend of naturally derived extracts》。
实验目的和原理:评价待测样品的抗皱、去黑眼圈等功效。
指标:
(1)黑色素:皮肤黑色素含量,基于光谱吸收原理(RGB);
(2)弹性(RT):皮肤回弹时间,吸盘原理;
(3)皱纹(SEw):皮肤皱纹程度。VC98CCD测试系统;
(4)胶原密度:真皮层胶原密度,超声原理。拍照设备:VISIA。
本次实验采用德国CK公司的多功能皮肤测试系统MPA6中的MX18黑色素和血红素测试探头,对皮肤黑色素的含量进行测试;以及VC98探头,测试皮肤皱纹程度(SEw),以及丹麦Cortex公司的多功能皮肤检测仪DermaLab Combo中的Ultrasound超声探头,对皮肤胶原回声密度进行测试,以及Elasticity弹性探头,对皮肤弹性进行测试,以及用VISIA进行面部拍照。
受试者筛选:30-60年龄(妊娠期或者哺乳期的妇女除外),无严重系统性疾病、无免疫缺陷或者自身免疫性疾病患者,受试部位无接触过皮肤治疗、美容以及其它可能影响结果的测试;无活动性过敏性疾病患者,无体质高度敏感者;近一个月无全身使用激素类药物以及免疫抑制剂者,显著或者最近三个月受试部位未参加其他临床试验者。
受试人数:32例受试者。
试验方案设计:选择脸部眼周围部位进行测试,周期为58d,测试时间分别为使用样品的0d,7d,14d,28d,56d。
测试方案:前后对照测试,检测受试者涂抹样品前的基础值,以及7d,14d,28d,56d的各项指标值。
检测指标为:黑色素、弹性(RT),皱纹(SEw),胶原密度测试部位如图7所示:
环境条件:于恒温恒湿室内进行测试,受试者在温度20℃~22℃,湿度40-60%的实验环境中适应20-30min。
产品使用方法:早上和晚上使用,使用量为1泵/每眼,均匀涂抹按摩,同时做好防晒,避免熬夜。
试验流程:受试者部位选择左、右眼周部位,具体测试步骤如下:
(1)使用清水清洗面部,恒温恒湿内平衡20min。
(2)受试者签署《知情同意书》,并对检测项目进行降解。
(3)皮肤科医生进行眼部皮肤状态评分。
(4)用MX18黑色素和血红素测试探头检测左眼下部位初始皮肤黑色素含量;使用VC98探头测试右眼下部位皱纹程度;使用Ultrasound探头测试右眼角部位皮肤胶原密度含量,使用Elasticity探头测试左眼角部位皮肤弹性回弹时间,以上测试每个区域重复测试3次,取平均值作为最终测试的数值,用VISIA进行面部的拍照。
(5)讲解眼霜使用方法和要求。
(6)使用产品的7d,14d,28d,56d时重复进行a,c步骤检测。
(7)皮肤科医生对眼部状态进行评分。
数据分析:GraphPad Prism 7软件进行数据分析,若测试数据满足正态分布采用T-test分析,如不满足正态分布,采用秩和检验计算统计学差异,统计方法采用双尾检测,检测水准α=0.05。
测试结果:
表9黑色素含量
样品 | 0d | 7d | 14d | 56d |
实施例1 | 202.01±40.53 | 194.55±42.30 | 193.60±35.75 | 169.15±37.14 |
实施例2 | 201.37±37.84 | 198.32±38.90 | 199.32±29.43 | 198.10±30.94 |
实施例3 | 203.22±41.30 | 201.10±41.03 | 199.57±58.59 | 199.04±19.84 |
实施例4 | 200.98±39.33 | 195.32±25.48 | 193.10±10.98 | 168.33±37.64 |
对比例1 | 204.53±39.81 | 198.71±37.70 | 195.33±25.09 | 173.45±46.53 |
对比例2 | 200.38±40.05 | 201.27±53.32 | 200.89±56.90 | 199.87±33.04 |
结论:在使用实施例1样品56d后,受试者眼周黑色素下降16.27%,与使用前0d相比,具有显著差异。
表10皮肤弹性(RT)
结论:使用实施例1样品56d后,受试者眼周皮肤弹性测试中,皮肤回弹时间降低8.38%,与使用前0d相比,皮肤弹性增加,具有显著性差异。
表11皮肤皱纹(SEw)程度
结论:由上述数据可知,使用实施例1样品56d后,受试者眼周围皮肤皱纹程度SEw减少13.19%,与使用前0d相比,有显著性差异。
表12皮肤胶原密度
样品 | 0d | 7d | 14d | 28d | 56d |
实施例1 | 42.12±9.14 | 43.84±7.76 | 48.82±8.07 | 47.59±7.87 | 48.54±8.68 |
实施例2 | 41.30±9.42 | 41.98±8.32 | 41.83±9.20 | 41.50±6.04 | 42.10±7.37 |
实施例3 | 40.98±8.45 | 41.11±9.43 | 41.53±8.04 | 42.09±7.04 | 41.86±6.50 |
实施例4 | 44.40±8.50 | 42.89±6.32 | 42.76±7.39 | 42.38±6.31 | 41.54±6.20 |
对比例1 | 41.39±7.10 | 41.10±5.98 | 40.98±8.34 | 40.53±5.32 | 40.16±9.30 |
对比例2 | 42.87±4.50 | 42.03±8.35 | 42.52±5.29 | 41.89±6.36 | 40.39±8.05 |
结论:使用实施例1样品56d后,受试者眼周皮肤胶原密度增加15.22%,与使用前0d对比,具有显著差异。
以上仅为本发明的实施例,并非因此限制本发明的专利范围,凡是利用本发明说明书内容所作等同变换,或直接或间接运用在相关的技术领域,均同理包括在本发明的专利保护范围内。
Claims (7)
1.一种低刺激高活性日间眼霜,其特征在于,其组成及重量份数为,VC-IP3~10份,VC乙基醚2~5份,缓释微囊体0~1份,曲克芦丁0.1~1份,浮游生物提取物溶液0.1~2份,拟南芥提取物溶液0.1~2份,环糊精包裹的咖啡因1~8份,七叶树皂苷0.1~2份,双效肉毒肽为1~10份,其它基础成分加至100份。
2.根据权利要求1所述的低刺激高活性日间眼霜,其特征在于,所述的缓释微囊体由水、卵磷脂、甘油、1,2戊二醇、生育酚、氢氧化钠通过高压微射流技术得到。
3.根据权利要求1所述的低刺激高活性日间眼霜,其特征在于,所述的基础成分包括溶剂、螯合剂、保湿剂、防腐剂、pH调节剂、抗氧化剂、乳化剂、增稠剂、填充剂。
4.根据权利要求3所述的低刺激高活性日间眼霜,其特征在于,所述的溶剂为去离子水,螯合剂为EDTA-2钠和/或植酸钠。
5.根据权利要求3所述的低刺激高活性日间眼霜,其特征在于,所述的保湿剂为多元醇(甘油、戊二醇、丁二醇、丙二醇、己二醇、辛甘醇、双丙甘醇、甲基丙二醇等)、聚二甲基硅氧烷(包括不同粘度)、C10-18脂酸甘油三酯类、辛酸/癸酸甘油三酯中的一种或者多种;
防腐剂为对羟基苯乙酮和/或苯氧乙醇;
pH调节剂为精氨酸、氢氧化钠、柠檬酸钠、柠檬酸中的一种或者多种;
抗氧化剂为生育酚乙酸酯、生育酚、季戊四醇四(双-叔丁基羟基氢化肉桂酸)酯中的一种或者多种。
6.根据权利要求3所述的低刺激高活性日间眼霜,其特征在于,所述的乳化剂为双-PEG/PPG-20/5PEG/PPG-20/5聚二甲基硅氧烷、甲氧基PEG/PPG-25/4聚二甲基硅氧烷、鲸蜡硬脂醇、菊粉月桂基氨基甲酸酯、聚甘油-2二异硬脂酸酯、聚甘油-3聚二甲基硅羟乙基聚二甲基硅氧烷、PEG/PPG-14/7二甲基醚、月桂基PEG/PPG-18/18聚甲基硅氧烷、PEG/PPG-18/18聚二甲基硅氧烷、月桂基PEG-10三(三甲硅氧烷)甲硅烷氧乙基聚二甲基硅氧烷、鲸蜡基PEG/PPG-10/1聚二甲基硅氧烷、聚甘油-4异硬脂酸酯、聚甘油-4二异硬脂酸酯/聚羟基硬脂酸酯/癸二酸酯、山梨坦倍半油酸酯、山梨坦倍半异硬脂酸酯、PEG-20甘油三异硬脂酸酯、PEG-40氢化蓖麻油、聚甘油-3聚蓖麻醇酸酯、聚甘油-6聚蓖麻醇酸酯、月桂基PEG-9聚二甲基硅氧乙基聚二甲基硅氧烷、PEG-30二聚羟基硬脂酸酯、双-PEG/PPG-14/14聚二甲基硅氧烷中的一种或者多种;
增稠剂为丙烯酰二甲基牛磺酸铵/VP、PVP共聚物中的一种或者多种;
填充剂(硅弹体)为聚二甲基硅氧烷/乙烯基三甲基硅烷氧基硅酸酯交联聚合物、聚二甲基硅氧烷交联聚合物、聚二甲基硅氧烷/乙烯基聚二甲基硅氧烷交联聚合物中的一种或者多种。
7.一种权利要求1所述的低刺激高活性日间眼霜的制备方法,其特征在于,具体的制备方法为,
(1)将溶剂、防腐剂、螯合剂、保湿剂加入到水相锅中,保持温度35~45℃,搅拌速度30~50r/min,恒温搅拌10~30min,均质5~15min,均质速度为2000~3500r/min,直到水相中物料完全溶解均匀,然后将增稠剂加入水相锅中进行溶解,得到具有一定稠度的液体,保持35~40℃,然后加入环糊精包裹的咖啡因、曲克芦丁、双效肉毒肽、浮游生物提取物溶液、拟南芥提取物溶液、七叶树皂苷,继续搅拌至溶解;
(2)将抗氧化剂、乳化剂、填充剂加入到乳化锅中,保持温度65~85℃,搅拌速度30~50r/min,恒温搅拌10~30min,均质5~15min,均质速度为2000~3500r/min,直到物料完全溶解均匀,降温至35~40℃;
(3)将步骤1)制得的混合物料边搅拌边缓慢加入到步骤2)的乳化锅中,继续搅拌直至溶解;
(4)预处理过程,将VC-IP和VC乙基醚加入到缓释微囊体中高速搅拌3500~10000rpm,直至溶液均匀分散;
(5)将步骤4)预处理后的物料加入到步骤3)的乳化锅中,保持原有温度继续搅拌,搅拌速度30~50r/min,然后加入pH调节剂调节体系的PH值为4.0~7.5,继续搅拌;
(6)最后将混合物料降温至25~38℃,检验、过滤、出料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310415179.6A CN116999346A (zh) | 2023-04-18 | 2023-04-18 | 一种低刺激高活性日间眼霜及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310415179.6A CN116999346A (zh) | 2023-04-18 | 2023-04-18 | 一种低刺激高活性日间眼霜及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116999346A true CN116999346A (zh) | 2023-11-07 |
Family
ID=88567914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310415179.6A Pending CN116999346A (zh) | 2023-04-18 | 2023-04-18 | 一种低刺激高活性日间眼霜及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116999346A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118319798A (zh) * | 2024-06-14 | 2024-07-12 | 苏州工业园区安诺科斯化妆品研发有限公司 | 一种防晒组合物及其制备方法 |
-
2023
- 2023-04-18 CN CN202310415179.6A patent/CN116999346A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118319798A (zh) * | 2024-06-14 | 2024-07-12 | 苏州工业园区安诺科斯化妆品研发有限公司 | 一种防晒组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100943366B1 (ko) | 피부 화장료 및 주름 개선제 | |
CN103479538B (zh) | 含有人参的花或人参的种子提取物的皮肤外用剂组合物 | |
WO2020024703A1 (zh) | 一种水溶性富勒烯外用组合物 | |
US8808761B2 (en) | Composition of skin external application containing rose extract and epigallocatechin gallate(EGCG) | |
JP5860983B2 (ja) | レウコユム球根の抽出物及びその利用 | |
KR101746639B1 (ko) | 봉독 추출물을 함유하는 피부 미백 및 보습용 조성물 | |
KR101500191B1 (ko) | 피부 케어용 조성물 및 이의 제조 방법 | |
JP2019510029A (ja) | 植物抽出物を含む局所用組成物 | |
CN114224787A (zh) | 包含植物种子油脂的组合物及其应用 | |
JP2010511376A (ja) | 皮膚バリア機能の鑑別法、これを用いた皮膚バリア機能強化素材のスクリーニング法、該皮膚バリア機能強化素材、及び該皮膚バリア機能強化素材を含有してなる化粧料 | |
CN116999346A (zh) | 一种低刺激高活性日间眼霜及其制备方法 | |
CN113041172A (zh) | 用于肌肤屏障修护的皮脂膜仿生组合物及其应用和化妆品 | |
CN116350550A (zh) | 一种具有保湿舒缓功效的面霜及其制备方法 | |
CN110075003A (zh) | 一种含有β-葡聚糖的补水祛斑霜及其制备方法 | |
JP2008088075A (ja) | プロフィラグリン/フィラグリン産生促進剤、表皮角化細胞増殖促進剤、表皮/角層正常化用皮膚外用剤、プロフィラグリン及び/又はフィラグリン産生促進方法、及び表皮角化細胞増殖促進方法 | |
KR101857282B1 (ko) | 패 추출물을 포함하는 화장료 조성물 | |
CN116459172A (zh) | 蔓荆子黄素的抗糖化应用 | |
CN115400067A (zh) | 用于皮肤的美白组合物 | |
CN113171316A (zh) | 一种修复、缓解皮肤刺激化妆品及制备方法 | |
JP3083105B2 (ja) | 化粧料 | |
KR20160020038A (ko) | 프랜지패니 오일 또는 프랜지패니 오일의 발효물을 포함하는 화장료 조성물 | |
CN116327643B (zh) | 一种经皮促渗组合物及其制备方法和在洗护产品中的应用 | |
CN113509429B (zh) | 一种含有鲟鱼子酱提取物的脂质体抗皱组合物及其制备方法和应用 | |
KR20190073478A (ko) | 주름 개선제 | |
CN115957173B (zh) | 一种具有皮肤屏障修复功效的组合物及其在化妆品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |